Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Eye (London, England)|December 5, 2024
Faricimab maintains substance integrity and sterility after compounding and storage in two different polypropylene syringe typesAlexander Taschauer, Arthur Sedivy, Daniel Egger, et al.
BMJ Open|December 22, 2021
Efficiency benchmarks in the surgical management of primary rhegmatogenous retinal detachment: a monocentric register cohort study of operating room time metrics and influential factorsReinhard Angermann, Anna Lena Huber, Markus Hofer, et al.
Current Eye Research|November 28, 2017
Effects of Intravitreal Aflibercept on Galectin-1 and Vascular Endothelial Growth Factor-A Plasma Levels in Patients with Diabetic RetinopathyInga Waltl, Claus Zehetner, Christof Seifarth, et al.
Clinical & Experimental Ophthalmology|April 17, 2021
Impact of submacular fluid volume on visual outcome in macula-off rhegmatogenous retinal detachment using automated optical coherence tomography volumetric quantificationReinhard Angermann, Stefan Mosböck, Christoph Palme, et al.
Acta Ophthalmologica|June 19, 2021
The impact of compliance among patients with diabetic macular oedema treated with intravitreal aflibercept: a 48-month follow-up studyReinhard Angermann, Markus Hofer, Anna Lena Huber, et al.
Klinische Monatsblatter Fur Augenheilkunde|April 21, 2022
The Impact of the COVID-19 Pandemic on the Quality of Care of Treatment-Naïve Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal AfliberceptReinhard Angermann, Alexander Franchi, Katharina Frede, et al.
Acta Ophthalmologica|June 3, 2021
Bilateral cataract surgery improves neurologic brake reaction time and stopping distance in elderly driversYvonne Nowosielski, Benedikt Leitner, Teresa Rauchegger, et al.
Retina (Philadelphia, Pa.)|November 3, 2021
CHANGES IN SYSTEMIC LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER INTRAVITREAL INJECTION OF AFLIBERCEPT OR BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATIONReinhard Angermann, Anna Lena Huber, Yvonne Nowosielski, et al.
Acta Ophthalmologica|December 16, 2020
Systemic counterregulatory response of angiopoietin-2 after aflibercept therapy for nAMD: a potential escape mechanismReinhard Angermann, Teresa Rauchegger, Yvonne Nowosielski, et al.
Ophthalmology and Therapy|January 20, 2022
Intravitreal Aflibercept Therapy and Treatment Outcomes of Eyes with Neovascular Age-Related Macular Degeneration in a Real-Life Setting: A Five-Year Follow-Up InvestigationReinhard Angermann, Alexander Franchi, Victoria Stöckl, et al.
Pageof 3